Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$4.58 - $8.34 $2.64 Million - $4.81 Million
576,603 Added 326.76%
753,064 $3.51 Million
Q1 2021

May 17, 2021

BUY
$20.38 - $34.07 $1.34 Million - $2.23 Million
65,573 Added 59.13%
176,461 $3.9 Million
Q4 2020

Feb 16, 2021

SELL
$19.0 - $32.63 $221,236 - $379,943
-11,644 Reduced 9.5%
110,888 $3.43 Million
Q3 2020

Nov 16, 2020

BUY
$13.1 - $20.69 $1.61 Million - $2.54 Million
122,532 New
122,532 $2.49 Million

About TCR2 THERAPEUTICS INC.


  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.